CervoMed CRVO 深 沪
等待开盘 11-10 09:30:00 美东时间
1.43
+0.010
+0.70%
华盛通- 最 高1.45
- 今 开1.39
- 成交量 31.52万股
- 最 低 1.3401
- 昨 收 1.42
- 总市值 2162.03万
- 52周最高 10.00
- 市盈率 静 --
- 换手率 2.08%
- 52周最低 1.27
- 委 比 -93.17%
- 总股本 1511.91万
- 历史最高 17437.50
- 量 比 0.80
- 振 幅 7.74%
- 历史最低 1.27
- 每 手 1
- 风险率 2.09%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多CervoMed Reports Third Quarter 2026 Financial Results and Provides Corporate Updates
CervoMed reported Q3 2026 financial results and updates on neflamapimod's development for treating neurodegenerative disorders. The company highlighted advancements in DLB, FTD, and stroke recovery, including biomarker data and regulatory milestones. Anticipated milestones include 24-week biomarker data at CTAD 2026 and the start of ALS trials in early 2027. Cash reserves of $19.6M are expected to support operations through Q3 2027.
11-09 12:30
CervoMed Announces Publication of Two Peer-Reviewed Research Articles Supporting Neflamapimod as a Potential Treatment for Dementia with Lewy Bodies (DLB)
Results from CervoMed's Phase 2b RewinD-LB trial of neflamapimod in dementia with Lewy bodies (DLB) published in *Alzheimer’s Research & Therapy* and *Cells* suggest the drug may slow disease progression by inhibiting neuroinflammation. Neflamapimod showed benefits in patients without Alzheimer’s co-pathology, improving cognitive measures and reducing biomarkers of neurodegeneration. The drug's effectiveness was linked to achieving target plasma ...
10-29 11:30
CervoMed Updates Investors with New Regulatory Presentation
CervoMed ( ($CRVO) ) has issued an update. CervoMed Inc. has made summary infor...
10-15 04:30
CervoMed Announces Data From Its Phase 2a Clinical Study Of Nonfluent Variant Primary Progressive Aphasia Shows Reduction In Mean Plasma Levels Of Neurofilament Light Chain
CervoMed Inc. (NASDAQ: CRVO) (CervoMed or the Company) announced initial data showing a reduction in mean plasma levels of neurofilament light chain (NfL), a key biomarker of neuronal damage and degeneration, over the first 12 weeks of treatment with neflamapimod in the open-label portion of the Com...
10-12 19:36
CervoMed Updates Investor Presentation and Disclosure Practices
The latest announcement is out from CervoMed ( ($CRVO) ). CervoMed announced th...
10-10 04:29
美股大行评级 | 瑞银维持康宁“买入”评级，上调目标价至201美元；大摩维持泛林集团“超配”评级
今日重点评级关注：Needham：维持iRhythm Holdings"买入"评级，目标价从192美元升至194美元；HC Wainwright & Co.：维持5E Advanced Materials"买入"评级，目标价从3.5美元升至6.75美元
10-06 16:45
HC Wainwright & Co. Reiterates Buy on CervoMed, Maintains $25 Price Target
HC Wainwright & Co. analyst Raghuram Selvaraju reiterates CervoMed (NASDAQ:CRVO) with a Buy and maintains $25 price target.
10-05 19:25
CervoMed Advances Neflamapimod Tablet and Dosing Strategy
An announcement from CervoMed ( ($CRVO) ) is now available. On September 28, 20...
09-29 05:26
CervoMed to Participate in the 5th Annual ROTH Healthcare Opportunities Conference
CervoMed Inc. announced that its management will participate in the 5th Annual ROTH Healthcare Opportunities Conference in New York on September 29, 2026. The panel discussion titled "Frontiers in Neuroscience" will take place from 10:00 AM to 10:50 AM ET. CervoMed, a clinical-stage company developing treatments for age-related brain disorders, highlighted its lead drug candidate, neflamapimod, which targets neuroinflammation and neurodegeneratio...
09-22 11:30
CervoMed To Present Neflamapimod, Oral, Small Molecule, Drug Candidate Targeting Critical Disease Processes Underlying Degenerative Disorders Of Brain, At ISFTD Annual Meeting
12-week biomarker data to be highlighted at the International Society of Frontotemporal Dementias (ISFTD) Annual Meeting nfvPPA, the type of frontotemporal dementia (FTD) most commonly associated with tau pathology, currently has no approved treatments in the United States or European Union BOSTON, ...
09-10 19:33
